BIOMEDICAL CHROMATOGRAPHY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2023-10-08 ms6000001894179607 来自山东省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：针刺;代谢组学
经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。

32 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2021-07-13 ms2000000123809009

审稿速度:2.0 | 投稿命中率:75.0
经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利

73 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2023-10-09 QQ1819064266 来自河南省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：配方颗粒;质量控制;药理作用
经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。

29 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2017-10-05 ms1387707191880519

一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题

56 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2022-11-02 ms3000001737419146

请问一下大家，这个杂志的彩图需要收费吗

43 0

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2022-06-14 卡布死牛

偏重的研究方向：中药代谢
经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？

37 0

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2021-07-13 ms2000000123809009

审稿速度:2.0
经验分享：外审两个月，二审一个月，就接受了，无版面费

74 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2020-12-31 123c0168m30(暂无昵称)

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：中药;药代动力学
经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？

121 0

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2020-04-18 1488dc74m59暂无昵称

你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表:
审稿3个月了还是under review，急死

157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死

150 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2161494, encodeId=be082161494eb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：针刺;代谢组学 经验分享：四月份投稿，六月一审回来，小修返回后一般外审一个月左右，七月录用，可以选择非OA，八月中旬online。总体审稿速度很快，给分配的国人编辑，对国人很友好，外审专家也很专业严谨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa58305752, createdName=ms6000001894179607, createdTime=Sun Oct 08 09:47:07 CST 2023, time=2023-10-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=999029, encodeId=7f3499902911, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投这篇文章投了快一年了，到处碰壁，在老师的帮助下，找到了这个期刊，在2021年3月份投的稿件，外审两个月，5月底得到反馈，根据审稿人的意见修改文章（算是大修了），6月初上传修改稿，7月初文章被接受啦，投稿内容是中药不同部位活性成分的测定以及药理活性。编辑人也很好，给发邮件一般2，3天就可以收到回复。由于是在线出版的，并不需要版面费。投稿十分不容易，尤其是我们这种科研狗，苦苦挣扎在顺利毕业的边缘。祝大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:46:49 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2161770, encodeId=79112161e7015, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：配方颗粒;质量控制;药理作用 经验分享：三月投稿，六月给了大修，意见都是小意见，分配的国人编辑，修回后一个月接受，半个月见刊，见刊速度很快，编辑很友好，有两种发表模式：订阅模式和OA模式，看情况选择，订阅模式无版面费，OA模式大概25000元左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f798262504, createdName=QQ1819064266, createdTime=Mon Oct 09 16:42:20 CST 2023, time=2023-10-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=838604, encodeId=17718386047e, content=一个月给出审稿意见，还是比较快的，大修，修改后就直接录用了，主要是语言问题 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7055413998, createdName=ms1387707191880519, createdTime=Thu Oct 05 09:43:42 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098010, encodeId=ec1820980101c, content=请问一下大家，这个杂志的彩图需要收费吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5755615733, createdName=ms3000001737419146, createdTime=Wed Nov 02 09:34:54 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226302, encodeId=95221226302f6, content=偏重的研究方向：中药代谢 经验分享：贵期刊让提供数据可用说明我在手稿中写到The data used to support the findings of this study are included within the article.可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97a75707252, createdName=卡布死牛, createdTime=Tue Jun 14 00:40:35 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999034, encodeId=6a28999034a5, content=审稿速度:2.0 经验分享：外审两个月，二审一个月，就接受了，无版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c5547554, createdName=ms2000000123809009, createdTime=Tue Jul 13 09:55:50 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912615, encodeId=3ea8912615a9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：中药;药代动力学 经验分享：我的论文10月21号接收的，现在状态是Version of Record online，持续了将近一个月了。请问下各位发表过的大神，啥时候出年卷期，啥时候能检索到啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d78c2433711, createdName=123c0168m30(暂无昵称), createdTime=Thu Dec 31 17:00:51 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589179, encodeId=2d845891e95e, content=你好，请问稿件提高是图表和文章分开吗？化学式一定要在chemdraw 按要求画吗？157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, beContent=157****3961暂无昵称 2019-09-25 00:00:00 发表: 审稿3个月了还是under review，急死, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=211f5312359, createdName=1488dc74m59暂无昵称, createdTime=Sat Apr 18 00:00:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576923, encodeId=d54f5e692361, content=审稿3个月了还是under review，急死, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7be25192437, createdName=1471d186m61暂无昵称, createdTime=Wed Sep 25 00:00:00 CST 2019, time=2019-09-25, status=1, ipAttribution=)]

2019-09-25 1471d186m61暂无昵称

审稿3个月了还是under review，急死

170 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务